Inhibition of estrogen-independent mammary carcinogenesis by disruption of growth hormone signaling.
暂无分享,去创建一个
V. Ray | R. Mehta | K. Christov | Jeffrey E. Green | T. Unterman | J. Kopchick | D. Lantvit | S. Hedayat | K. Coschigano | S. Swanson | Xiao Zhang | Vera H Ray
[1] M. Pegram,et al. Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer , 2005, Investigational New Drugs.
[2] A. Turnley. Role of SOCS2 in growth hormone actions , 2005, Trends in Endocrinology & Metabolism.
[3] D. Yee,et al. Insulin-like growth factor-I and breast cancer therapy. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[4] J. Tobias. Endocrine approaches for the treatment of early and advanced breast cancer in postmenopausal women. , 2004, The international journal of biochemistry & cell biology.
[5] K. Ho,et al. Estrogen regulation of growth hormone action. , 2004, Endocrine reviews.
[6] K. Kinzler,et al. Cancer genes and the pathways they control , 2004, Nature Medicine.
[7] Jeffrey E. Green,et al. The use of genetically altered mice for breast cancer prevention studies. , 2003, The Journal of nutrition.
[8] C. Roberts,et al. The insulin-like growth factor system and cancer. , 2003, Cancer letters.
[9] N. Barnard,et al. The current use of estrogens for growth-suppressant therapy in adolescent girls. , 2002, Journal of pediatric and adolescent gynecology.
[10] J. A. Scarlett,et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist , 2001, The Lancet.
[11] J. Herrington,et al. Signaling pathways activated by the growth hormone receptor , 2001, Trends in Endocrinology & Metabolism.
[12] M. Bidlingmaier,et al. Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone antagonist , 2001, British Journal of Cancer.
[13] J. Sambrook,et al. Molecular Cloning: A Laboratory Manual , 2001 .
[14] K. Korach,et al. Estrogen promotes mammary tumor development in C3(1)/SV40 large T-antigen transgenic mice: paradoxical loss of estrogen receptoralpha expression during tumor progression. , 2000, Cancer research.
[15] R. Cardiff,et al. Genetically Engineered Mouse Models of Mammary Intraepithelial Neoplasia , 2000, Journal of Mammary Gland Biology and Neoplasia.
[16] R. Baxter,et al. Estrogens exert route- and dose-dependent effects on insulin-like growth factor (IGF)-binding protein-3 and the acid-labile subunit of the IGF ternary complex. , 2000, The Journal of clinical endocrinology and metabolism.
[17] A. Schally,et al. Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice , 2000, Breast Cancer Research and Treatment.
[18] Cheryl Jorcyk,et al. The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma , 2000, Oncogene.
[19] J. Kopchick,et al. Is the Laron mouse an accurate model of Laron syndrome? , 1999, Molecular genetics and metabolism.
[20] F. Talamantes,et al. Differential expression of the growth hormone receptor and growth hormone-binding protein in epithelia and stroma of the mouse mammary gland at various physiological stages. , 1999, The Journal of endocrinology.
[21] B. Groner,et al. Interactions in the transcriptional regulation exerted by Stat5 and by members of the steroid hormone receptor family , 1999, The Journal of Steroid Biochemistry and Molecular Biology.
[22] A. Bartke,et al. Pituitary and testicular function in growth hormone receptor gene knockout mice. , 1999, Endocrinology.
[23] J. Rosen,et al. Glucocorticoid receptor/signal transducer and activator of transcription 5 (STAT5) interactions enhance STAT5 activation by prolonging STAT5 DNA binding and tyrosine phosphorylation. , 1999, Molecular endocrinology.
[24] H. Scher,et al. Workgroup 3: Transgenic and reconstitution models of prostate cancer , 1998, The Prostate.
[25] M. Waters,et al. Cellular expression of growth hormone and prolactin receptors in human breast disorders , 1998, International journal of cancer.
[26] P. Walden,et al. Printed in U.S.A. Copyright © 1998 by The Endocrine Society Evidence That the Mammary Fat Pad Mediates the Action of Growth Hormone in Mammary Gland Development , 2022 .
[27] T. Wagner,et al. A mammalian model for Laron syndrome produced by targeted disruption of the mouse growth hormone receptor/binding protein gene (the Laron mouse). , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[28] D. Leroith,et al. Growth hormone treatment induces mammary gland hyperplasia in aging primates , 1997, Nature Medicine.
[29] Dr. Andreas von Deimling. Neoplasia , 1997, Laboratory investigation; a journal of technical methods and pathology.
[30] A. Siegbahn,et al. Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women. , 1997, The Journal of clinical endocrinology and metabolism.
[31] J. Ward,et al. p53-independent apoptosis during mammary tumor progression in C3(1)/SV40 large T antigen transgenic mice: suppression of apoptosis during the transition from preneoplasia to carcinoma. , 1996, Cancer research.
[32] H. Huynh,et al. Reduced growth of human breast cancer xenografts in hosts homozygous for the lit mutation. , 1996, Cancer research.
[33] G. Fuh,et al. Prolactin Receptor Antagonists That Inhibit the Growth of Breast Cancer Cell Lines (*) , 1995, The Journal of Biological Chemistry.
[34] J. Bonneterre,et al. Presence of the two growth hormone receptor messenger RNA isoforms in human breast cancer. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[35] J. Green,et al. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[36] B. Cunningham,et al. Evidence that the growth hormone receptor mediates differentiation and development of the mammary gland. , 1993, Endocrinology.
[37] K. Ho,et al. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. , 1991, The Journal of clinical endocrinology and metabolism.
[38] A. Fiennes,et al. Growth rate of tumours , 1988, The British journal of surgery.
[39] D. Clemmons,et al. Estradiol treatment of acromegaly. Reduction of immunoreactive somatomedin-C and improvement in metabolic status. , 1980, The American journal of medicine.
[40] B. Lord,et al. Growth Kinetics of Tumours , 1978, British Journal of Cancer.
[41] A. Jemal,et al. Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.
[42] T. Wood,et al. The Insulin-Like Growth Factors (IGFs) and IGF Binding Proteins in Postnatal Development of Murine Mammary Glands , 2004, Journal of Mammary Gland Biology and Neoplasia.
[43] L. Young,et al. Preparing Mammary Gland Whole Mounts from Mice , 2000 .
[44] B. Asch,et al. Methods in Mammary Gland Biology and Breast Cancer Research , 2000, Springer US.
[45] M. Waters,et al. Growth hormone receptor expression in the nucleus and cytoplasm of normal and neoplastic cells , 1998, Histochemistry and Cell Biology.
[46] P. Lobie,et al. Growth hormone receptors expression in the proliferating rat mammary gland. , 1990, Acta histochemica. Supplementband.
[47] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.